Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K
Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

3.0K
The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
3.0K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

725
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
725
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.9K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.9K
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

16
The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of nurses' knowledge and practices in healthcare-associated infections management following clinical pharmacist-led training in a Romanian clinical hospital using a questionnaire.

Journal of infection prevention·2026
Same author

Commentary: Rare earth elements affect the growth and fitness of free-floating plant <i>Lemna minor</i> L.

Frontiers in plant science·2026
Same author

Possible role of pre-vaccination T-lymphocyte subpopulations in the antibody response to COVID-19 vaccines in children undergoing chemotherapy.

Frontiers in immunology·2026
Same author

Hand hygiene compliance and glove use in intensive care units: a one-year observational study in Hungary.

The Journal of hospital infection·2025
Same author

[The role of molecular pathology in the diagnosis, prognosis, and management of childhood tumors].

Orvosi hetilap·2025
Same author

<i>Lemna gibba</i> Clones Show Differences in Phenotypic Responses to the Light Environment.

Plants (Basel, Switzerland)·2025

Related Experiment Video

Updated: Apr 19, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.7K

"Gastric cytoprotection" is still relevant.

Sandor Szabo1

  • 1Departments of Pathology and Pharmacology, University of California-Irvine and VA Medical Center, Long Beach, California, USA.

Journal of Gastroenterology and Hepatology
|December 19, 2014
PubMed
Summary

Gastric cytoprotection involves prostaglandins (PG) and sulfhydryls (SH), which protect the stomach lining by increasing vascular permeability and scavenging free radicals, respectively. This complex response aids in healing ulcers and preventing damage from irritants.

Keywords:
Angiogenic growth factorsGastric cytoprotectionGastroprotectionHistamineProstaglandinsSofalconeSucralfateSulfhydrylsUlcer healing

More Related Videos

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

10.3K

Related Experiment Videos

Last Updated: Apr 19, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.7K
One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

10.3K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Physiology

Background:

  • Gastric cytoprotection, introduced by Andre Robert in 1979, focuses on drugs that protect the gastric mucosa without inhibiting acid secretion.
  • Prostaglandins (PG) have been central to gastrointestinal research for over 30 years, implicated in mediating the effects of gastroprotective agents.
  • Sulfhydryls (SH) are another class of endogenous substances investigated for their role in gastroprotection, with SH alkylators counteracting protective effects.

Purpose of the Study:

  • To explore the mechanistic roles of endogenous substances like prostaglandins (PG) and sulfhydryls (SH) in acute gastric cytoprotection.
  • To propose a new mechanistic explanation for gastroprotection, integrating PG, SH, and histamine as key mediators.
  • To understand the role of increased vascular permeability (VP) in the protective response against chemically induced gastric mucosal lesions.

Main Methods:

  • Review of existing research on prostaglandins (PG) and sulfhydryls (SH) in gastric cytoprotection.
  • Analysis of the effects of cyclooxygenase inhibitors (e.g., indomethacin) and SH alkylators (e.g., N-ethylmaleimide) on gastroprotection.
  • Formulation of a new mechanistic model based on physiological defense responses, including inflammation and vascular changes.

Main Results:

  • No single mechanism explains all forms of gastroprotection; PG and histamine increase vascular permeability (VP), creating a protective edema.
  • Sulfhydryls (SH) function as free radical scavengers, contributing to the overall protective effect.
  • A slight increase in VP, mediated by PG and histamine, is proposed as a key protective element in acute gastroprotection, diluting toxic agents.

Conclusions:

  • Acute gastroprotection is a complex, evolution-based physiological response involving PG, histamine, and SH.
  • Increased VP, mucus, and bicarbonate secretion contribute to diluting and delaying gastrotoxic agents.
  • Further research is needed to effectively treat ulcers and prevent drug-induced gastrointestinal damage, highlighting the continued relevance of gastric cytoprotection studies.